Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA’s journals — Clinical Gastroenterology and Hepatology and Gastroenterology — highlight important updates into treatments for these two debilitating diseases.
Promising Probiotic for Liver Disease
A study published in Gastroenterology found that, over a six-month period, daily intake of the probiotic VSL#3® significantly improved liver function and reduced the risk of hospitalization in patients with cirrhosis.
Drug Reduces Liver Fat Content in NAFLD Patients
Publishing in Clinical Gastroenterology and Hepatology, researchers report that three months’ administration of the fatty acid/bile acid conjugate Aramchol is safe, tolerable and significantly reduces liver fat content in patients with NAFLD.
Resveratrol Does Not Benefit Patients with NAFLD
Reporting in Clinical Gastroenterology and Hepatology, researchers find that eight weeks administration of resveratrol did not induce therapeutic benefits in men with established NAFLD, compared with placebo.
This research was supported by the Princess Alexandra Research Foundation, the Lions Medical Research Foundation, and the National Health and Medical Research Council of Australia.
Source : Science Discover